IP Library › Granted Patent US 12,746,317
Granted Patent B2
US 12,746,317 · App. 16/149,538 · Granted Sep 29, 2026

Systems and methods for returning treated mononuclear cells to a blood source

Inventor: Tanima Jahan Abedin (Chicago, IL)
Assignee: Fenwal, Inc.
A61M1/3683A61M1/0209A61M1/362227A61M1/36225A61M1/3643A61M1/3644A61M1/3693A61M1/38A61K35/15A61K35/17A61M2202/0407A61M2202/0415A61M2202/0427A61M2202/0429A61M2202/0439A61M2202/0443A61M2202/0447A61M2205/051A61M2205/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,746,317
App. No.
16/149,538
Granted
Sep 29, 2026
Kind
B2
Abstract

A method for treating mononuclear cells for an extracorporeal photopheresis procedure, driven and adjusted by a microprocessor-based controller, comprising the steps of priming a fluid circuit with priming fluid, directing whole blood derived from a blood source into the fluid circuit, separating the whole blood into a red blood cell component, a mononuclear cell component, and a plasma component, returning a first portion of the red blood cell component and a first portion of the plasma component to the whole blood, adding a photoactivation agent to the mononuclear cell component to create an agent-added mononuclear cell component, irradiating the agent-added mononuclear cell component to create a photoactivated mononuclear cell component, and incubating for a period of time a first portion of the photoactivated mononuclear cell component to create an incubated photoactivated mononuclear cell component.

Claims (38)

1 . A method for treating mononuclear cells for an extracorporeal photopheresis procedure, driven and adjusted by a microprocessor-based controller, comprising the steps of:

priming a fluid circuit with priming fluid;

directing whole blood derived from a blood source into the fluid circuit;

separating the whole blood in a separation chamber of the fluid circuit into a red blood cell component, a mononuclear cell component, and a platelet/plasma component;

returning a first portion of the red blood cell component and a first portion of the platelet/plasma component to the whole blood at the same time as the mononuclear cell component is accumulating in the separation chamber;

adding a biological agent to the mononuclear cell component in an illumination container fluidically connected to the separation chamber to create an agent-added mononuclear cell component;

irradiating the agent-added mononuclear cell component in an illumination container of the fluid circuit; and

after irradiation of the agent-added mononuclear cell component has ended, incubating for a period of time a first portion of the agent-added mononuclear cell component in the illumination container to create an incubated agent-added mononuclear cell component, with the blood source being disconnected from the fluid circuit for at least a portion of the period of time, wherein

the period of time is sufficiently long to allow for apoptotic T-cells generated in the agent-added mononuclear cell component by irradiation to induce differentiation of monocytes in the first portion of the agent-added mononuclear cell component into dendritic cells, and

a single fluid circuit is used for both separating the whole blood and incubating the first portion of the agent-added mononuclear cell component.

2 . The method of claim 1 , further comprising:

retaining a second portion of the red blood cell component and a second portion of the platelet/plasma component within the fluid circuit prior to adding the biological agent; and

reinfusing into the blood source the second portion of the red blood cell component and the second portion of the platelet/plasma component.

3 . The method of claim 1 , wherein the priming fluid comprises at least one of albumin and a blood component.

4 . The method of claim 1 , wherein the priming fluid comprises saline.

5 . The method of claim 1 , wherein

the biological agent comprises a photoactivation agent,

the agent-added mononuclear cell component is irradiated to create a photoactivated mononuclear cell component prior to incubation, and

said incubating for a period of time a first portion of the agent-added mononuclear cell component in the illumination container to create an incubated agent-added mononuclear cell component comprises incubating for said period of time a first portion of the photoactivated mononuclear cell component in the illumination container to create an incubated photoactivated mononuclear cell component.

6 . The method of claim 1 , further comprising retaining a second portion of the red blood cell component and a second portion of the platelet/plasma component within the fluid circuit without returning to the blood source.

7 . The method of claim 5 , further comprising disconnecting the blood source from the fluid circuit while incubating said first portion of the photoactivated mononuclear cell component.

8 . The method of claim 7 , further comprising reinfusing a portion of the incubated photoactivated mononuclear cell component into the blood source.

9 . The method of claim 1 , further comprising washing at least a portion of the incubated agent-added mononuclear cell component.

10 . The method of claim 1 , further comprising returning a portion of the priming fluid to the blood source.

11 . The method of claim 1 , further comprising reinfusing a second portion of the agent-added mononuclear cell component.

12 . The method of claim 1 , further comprising reinfusing a first portion of the incubated agent-added mononuclear cell component to the blood source.

13 . The method of claim 12 , further comprising collecting a second portion of the incubated agent-added mononuclear cell component without reinfusion to the blood source.

14 . The method of claim 1 , further comprising reinfusing none of the incubated agent-added mononuclear cell component to the blood source.

15 . The method of claim 5 , further comprising

retaining a second portion of the red blood cell component and a second portion of the platelet/plasma component within the fluid circuit prior to adding the photoactivation agent, and

reinfusing into the blood source the second portion of the red blood cell component and the second portion of the platelet/plasma component at the same time as irradiating the agent-added mononuclear cell component.

16 . The method of claim 5 , further comprising reinfusing a second portion of the photoactivated mononuclear cell component.

17 . The method of claim 5 , further comprising reinfusing a first portion of the incubated photoactivated mononuclear cell component to the blood source.

18 . The method of claim 17 , further comprising collecting a second portion of the incubated photoactivated mononuclear cell component without reinfusion to the blood source.

19 . The method of claim 5 , further comprising reinfusing none of the incubated photoactivated mononuclear cell component to the blood source.

20 . The method of claim 1 , wherein

the whole blood is directed into the fluid circuit via an access device of the fluid circuit connected to the blood source, and

the blood source is disconnected from the access device of the fluid circuit for said at least a portion of the period of time.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: ABEDIN, TANIMA JAHAN
To: FENWAL, INC.
Reel/Frame 047037/0868 →
Continuity (2)
Provisional Application 62567026 · Oct 2, 2017
Related Publication 20190099544A1 · Apr 4, 2019
References Cited (16)
US 4568328A · King · 1986 [cited by examiner]
US 4623328A · Hartranft · 1986 [cited by applicant]
US 5360542A · Williamson, IV et al. · 1994 [cited by applicant]
US 5868696A · Giesler et al. · 1999 [cited by applicant]
US 6027657A · Min et al. · 2000 [cited by applicant]
US 7433030B2 · Waldo et al. · 2008 [cited by applicant]
US 20060155236A1 · Gara · 2006 [cited by examiner]
US 20080241815A1 · Edelson et al. · 2008 [cited by applicant]
US 20180256805A1 · Nguyen · 2018 [cited by examiner]
EP 2641623A1 · 2013 [cited by applicant]
WO 1999003976A2 · 1999 [cited by applicant]
WO 2016205511A1 · 2016 [cited by applicant]
Durazzo et al. “Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling.” Transfusion and Apheresis Science 50.3 (2014): 370-378. (Year: 2014). [cited by examiner]
Girardi et al. “Transimmunization for cutaneous T cell lymphoma: a Phase I study.” Leukemia & lymphoma 47.8 (2006): 1495-1503. (Year: 2006). [cited by examiner]
Florek, M., et al. “Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft versus-host models . . .” Blood. Sep. 11, 2014. vol. 124, No. 11. [cited by applicant]
Partial European Search Report for counterpart EP Application No. 18196602.9 (Feb. 15, 2019) (18 pages). [cited by applicant]